<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYMBALTA- duloxetine hydrochloride capsule, delayed release </strong><br>Rebel Distributors Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
These highlights do not include all the information needed to use CYMBALTA safely and effectively. See full prescribing information for CYMBALTA. <br>
CYMBALTA (duloxetine hydrochloride) capsule, delayed release for oral use <br>
Initial U.S. Approval: 2004
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: Suicidality and Antidepressant Drugs</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc"><li><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Cymbalta is not approved for use in pediatric patients (<a href="#s31">5.1</a>).</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">
Indications and Usage,  <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (<a href="#s5">1.2</a>)                     11/2009 </p>
<p class="Highlighta">
Dosage and Administration, Maintenance/Continuation/Extended
Treatment (<a href="#s13">2.2</a>)                     11/2009 </p>
<p class="Highlighta">
Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like Reactions (<a href="#s35">5.4</a>)                     01/2009 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: Suicidality and Antidepressant Drugs</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc"><li><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Cymbalta is not approved for use in pediatric patients (<a href="#s31">5.1</a>).</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Cymbalta<span class="Sup">®</span> is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: </p>
<ul class="Disc">
<li>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) (<a href="#s4">1.1</a>)<br>Efficacy was established in 4 short-term and one maintenance trial in adults (<a href="#s119">14.1</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span> (GAD) (<a href="#s5">1.2</a>)<br>Efficacy was established in 3 short-term and one maintenance trial in adults (<a href="#s120">14.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span> (DPNP) (<a href="#s6">1.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> (FM) (<a href="#e7">1.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc"><li>Cymbalta should generally be administered once daily without regard to meals. Cymbalta should be swallowed whole and should not be chewed or crushed, nor should the capsule be opened and its contents be sprinkled on food or mixed with liquids (<a href="#s9">2.1</a>).</li></ul>
<table width="100%">
<col align="left" width="22.550%">
<col align="left" width="23.800%">
<col align="left" width="31.525%">
<col align="left" width="22.125%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">
Indication
</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">
Starting Dose
</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">
Target Dose
</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">
Maximum Dose
</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">
MDD (2.1, 2.2)
</td>
<td class="Botrule Rrule" align="left" valign="top">
40 mg/day to 60 mg/day
</td>
<td class="Botrule Rrule" align="left" valign="top">
Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day
</td>
<td class="Botrule Rrule" align="left" valign="top">
120 mg/day
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
GAD (2.1)
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day (once daily)
</td>
<td class="Botrule Rrule" align="left" valign="top">
120 mg/day
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
DPNP (2.1)
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day (once daily)
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
FM (2.1)
</td>
<td class="Botrule Rrule" align="left" valign="top">
30 mg/day
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day (once daily)
</td>
<td class="Botrule Rrule" align="left" valign="top">
60 mg/day
</td>
</tr>
</tbody>
</table>
<ul class="Disc">
<li>Some patients may benefit from starting at 30 mg once daily.</li>
<li>There is no evidence that doses greater than 60 mg/day confers additional benefit, while some adverse reactions were observed to be dose-dependent.</li>
<li>Discontinuing Cymbalta: A gradual dose reduction is recommended to avoid discontinuation symptoms (<a href="#s37">5.6</a>).</li>
</ul>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>20 mg, 30 mg, and 60 mg capsules (<a href="#s25">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Use of a monoamine oxidase inhibitor concomitantly or in close temporal proximity (<a href="#s28">4.1</a>)</li>
<li>Use in patients with uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#s29">4.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Suicidality: Monitor for clinical worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk (<a href="#s31">5.1</a>).</li>
<li>Hepatotoxicity: <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span>, sometimes fatal, has been reported in patients treated with Cymbalta. Cymbalta should be discontinued in patients who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. Cymbalta should ordinarily not be prescribed to patients with substantial alcohol use or evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> (<a href="#s33">5.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>: Cases have been reported with duloxetine therapy (<a href="#s34">5.3</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>, or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like reactions: <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> or NMS-like reactions have been reported with SSRIs and SNRIs. Discontinue Cymbalta and initiate supportive treatment (<a href="#s35">5.4</a>, <a href="#s82">7.14</a>).</li>
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: Cymbalta may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation (<a href="#s36">5.5</a>, <a href="#s72">7.4</a>).</li>
<li>Discontinuation: May result in symptoms, including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (<a href="#s37">5.6</a>).</li>
<li>Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has occurred (<a href="#s38">5.7</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Prescribe with care in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder (<a href="#s39">5.8</a>).</li>
<li>Blood Pressure: Monitor blood pressure prior to initiating treatment and periodically throughout treatment (<a href="#s40">5.9</a>).</li>
<li>Inhibitors of CYP1A2 or Thioridazine: Should not administer with Cymbalta (<a href="#s41">5.10</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>: Cases of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> have been reported (<a href="#s45">5.11</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> and Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Should ordinarily not be administered to these patients (<a href="#s46">5.12</a>).</li>
<li>Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>: Use cautiously in these patients (<a href="#s46">5.12</a>).</li>
<li>Glucose Control in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>: In <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathic pain</span> patients, small increases in fasting blood glucose, HbA<span class="Sub">1c</span>, and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> have been observed (<a href="#s46">5.12</a>).</li>
<li>Conditions that Slow Gastric Emptying: Use cautiously in these patients (<a href="#s46">5.12</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary Hesitation</span> and Retention (<a href="#s51">5.13</a>).</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>Most common adverse reactions (≥5% and at least twice the incidence of placebo patients): <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (<a href="#s58">6.3</a>).</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Potent inhibitors of CYP1A2 should be avoided (<a href="#s69">7.1</a>).</li>
<li>Potent inhibitors of CYP2D6 may increase duloxetine concentrations (<a href="#s70">7.2</a>).</li>
<li>Duloxetine is a moderate inhibitor of CYP2D6 (<a href="#s77">7.9</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>Pregnancy and Nursing Mothers: Use only if the potential benefit justifies the potential risk to the fetus or child (<a href="#s17">2.3</a>, <a href="#s88">8.1</a>, <a href="#s92">8.3</a>).</li></ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4 <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Initial Treatment</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Maintenance/Continuation/Extended Treatment</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing in Special Populations</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Discontinuing Cymbalta</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching Patients to or from a Monoamine Oxidase Inhibitor</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Uncontrolled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hepatotoxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like Reactions</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Discontinuation of Treatment with Cymbalta</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Effect on Blood Pressure</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Clinically Important Drug Interactions</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Use in Patients with Concomitant Illness</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary Hesitation</span> and Retention</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Data Sources</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Adverse Reactions Reported as Reasons for Discontinuation of Treatment in Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Adverse Reactions Occurring at an Incidence of 5% or More and at least Twice Placebo Among Duloxetine-Treated Patients in Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Adverse Reactions Occurring at an Incidence of 5% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.5" class="toc">6.5 Adverse Reactions Occurring at an Incidence of 2% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.6" class="toc">6.6 Effects on Male and Female Sexual Function</a></h2>
<h2><a href="#section-6.7" class="toc">6.7 Vital Sign Changes</a></h2>
<h2><a href="#section-6.8" class="toc">6.8 Weight Changes</a></h2>
<h2><a href="#section-6.9" class="toc">6.9 Laboratory Changes</a></h2>
<h2><a href="#section-6.10" class="toc">6.10 Electrocardiogram Changes</a></h2>
<h2><a href="#section-6.11" class="toc">6.11 Other Adverse Reactions Observed During the Premarketing and Postmarketing Clinical Trial Evaluation of Duloxetine</a></h2>
<h2><a href="#section-6.12" class="toc">6.12 Postmarketing Spontaneous Reports</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Inhibitors of CYP1A2</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Inhibitors of CYP2D6</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Dual Inhibition of CYP1A2 and CYP2D6</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Lorazepam</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Temazepam</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Drugs that Affect Gastric Acidity</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Drugs Metabolized by CYP1A2</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Drugs Metabolized by CYP2D6</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 Drugs Metabolized by CYP2C9</a></h2>
<h2><a href="#section-7.11" class="toc">7.11 Drugs Metabolized by CYP3A</a></h2>
<h2><a href="#section-7.12" class="toc">7.12 Drugs Metabolized by CYP2C19</a></h2>
<h2><a href="#section-7.13" class="toc">7.13 Monoamine Oxidase Inhibitors</a></h2>
<h2><a href="#section-7.14" class="toc">7.14 Serotonergic Drugs</a></h2>
<h2><a href="#section-7.15" class="toc">7.15 Triptans</a></h2>
<h2><a href="#section-7.16" class="toc">7.16 Alcohol</a></h2>
<h2><a href="#section-7.17" class="toc">7.17 CNS Drugs</a></h2>
<h2><a href="#section-7.18" class="toc">7.18 Drugs Highly Bound to Plasma Protein</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Gender</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Smoking Status</a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Race</a></h2>
<h2><a href="#section-8.9" class="toc">8.9 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.10" class="toc">8.10 Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.2" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Signs and Symptoms</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
<h2><a href="#section-14.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></a></h2>
<h2><a href="#section-14.4" class="toc">14.4 <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information on Medication Guide</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Medication Administration</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Continuing the Therapy Prescribed</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Concomitant Medications</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-16.8" class="toc">17.8 Pregnancy and Breast Feeding</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Alcohol</a></h2>
<h2><a href="#section-16.10" class="toc">17.10 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h2><a href="#section-16.11" class="toc">17.11 Interference with Psychomotor Performance</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS</span></p>
<p><span class="Bold">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Cymbalta or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Cymbalta is not approved for use in pediatric patients.</span><span class="Bold Italics"> [see Warnings and Precautions (<a href="#s31">5.1</a>), Use in Specific Populations (<a href="#s93">8.4</a>), and Information for Patients (<a href="#s127">17.2</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First">Cymbalta is indicated for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults <span class="Italics">[see Clinical Studies (<a href="#s119">14.1</a>)]</span>.</p>
<p>A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, loss of interest in usual activities, significant change in weight and/or appetite, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> or retardation, increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, feelings of guilt or worthlessness, <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span> or impaired concentration, or a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Cymbalta is indicated for the treatment of generalized <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults <span class="Italics">[see Clinical Studies (<a href="#s120">14.2</a>)]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized anxiety disorder</span> is defined by the DSM-IV as excessive <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span>, present more days than not, for at least 6 months. The excessive <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, muscle <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, and/or <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></h2>
<p class="First">Cymbalta is indicated for the management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> (DPNP) associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span> <span class="Italics">[see Clinical Studies (<a href="#s121">14.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e7"></a><a name="section-1.4"></a><p></p>
<h2>1.4 <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></h2>
<p class="First">Cymbalta is indicated for the management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (FM) <span class="Italics">[see Clinical Studies (<a href="#e130">14.4</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Cymbalta should be swallowed whole and should not be chewed or crushed, nor should the capsule be opened and its contents sprinkled on food or mixed with liquids. All of these might affect the enteric coating. Cymbalta should be given without regard to meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Initial Treatment</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></span> — Cymbalta should be administered at a total dose of 40 mg/day (given as 20 mg twice daily) to 60 mg/day (given either once daily or as 30 mg twice daily). For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg/day dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer any additional benefits. The safety of doses above 120 mg/day has not been adequately evaluated <span class="Italics">[see Clinical Studies (<a href="#s119">14.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></span> — For most patients, the recommended starting dose for Cymbalta is 60 mg administered once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit. Nevertheless, if a decision is made to increase the dose beyond 60 mg once daily, dose increases should be in increments of 30 mg once daily. The safety of doses above 120 mg once daily has not been adequately evaluated <span class="Italics">[see Clinical Studies (<a href="#s120">14.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e11"></a><a name="section-2.1.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span> — The recommended dose for Cymbalta is 60 mg administered once daily. There is no evidence that doses higher than 60 mg confer additional significant benefit and the higher dose is clearly less well tolerated <span class="Italics">[see Clinical Studies (<a href="#s121">14.3</a>)]</span>. For patients for whom tolerability is a concern, a lower starting dose may be considered.</p>
<p>
											 Since <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> is frequently complicated by <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, a lower starting dose and gradual increase in dose should be considered for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Clinical Pharmacology (<a href="#s110">12.3</a>) and Dosage and Administration (<a href="#s17">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e13"></a><a name="section-2.1.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></span> — The recommended dose for Cymbalta is 60 mg administered once daily. Treatment should begin at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. Some patients may respond to the starting dose. There is no evidence that doses greater than 60 mg/day confer additional benefit, even in patients who do not respond to a 60 mg dose, and higher doses are associated with a higher rate of adverse reactions <span class="Italics">[see Clinical Studies (<a href="#e130">14.4</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Maintenance/Continuation/Extended Treatment</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.2.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></span> — It is generally agreed that acute episodes of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> require several months or longer of sustained pharmacologic therapy.  Maintenance of efficacy in MDD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered at a total dose of 60 mg once daily. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment <span class="Italics">[see Clinical Studies (<a href="#s119">14.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e16"></a><a name="section-2.2.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline"><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></span> — It is generally agreed that episodes of <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">generalized anxiety disorder</span> require several months or longer of sustained pharmacological therapy. Maintenance of efficacy in GAD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered in a dose range of 60-120 mg once daily. Patients should be periodically reassessed to determine the continued need for maintenance treatment and the appropriate dose for such treatment <span class="Italics">[see Clinical Studies (<a href="#s120">14.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e17"></a><a name="section-2.2.3"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline"><span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span> — As the progression of <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span> is highly variable and management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is empirical, the effectiveness of Cymbalta must be assessed individually. Efficacy beyond 12 weeks has not been systematically studied in placebo-controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e18"></a><a name="section-2.2.4"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span><span class="Underline"><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></span> — <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> is recognized as a chronic condition. The efficacy of Cymbalta in the management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> has been demonstrated in placebo-controlled studies up to 3 months. The efficacy of Cymbalta was not demonstrated in longer studies; however, continued treatment should be based on individual patient response.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing in Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span> — It is recommended that Cymbalta should ordinarily not be administered to patients with any <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see Warnings and Precautions (<a href="#s46">5.12</a>) and Use in Specific Populations (<a href="#s98">8.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span> — Cymbalta is not recommended for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (estimated creatinine clearance &lt;30 mL/min) <span class="Italics">[see Warnings and Precautions (<a href="#s46">5.12</a>) and Use in Specific Populations (<a href="#s99">8.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-2.3.3"></a><p></p>
<p class="First"><span class="Underline">Elderly Patients</span> — No dose adjustment is recommended for elderly patients on the basis of age. As with any drug, caution should be exercised in treating the elderly. When individualizing the dosage in elderly patients, extra care should be taken when increasing the dose <span class="Italics">[see Use in Specific Populations (<a href="#s94">8.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-2.3.4"></a><p></p>
<p class="First"><span class="Underline">Pregnant Women</span> — There are no adequate and well-controlled studies in pregnant women; therefore, Cymbalta should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus <span class="Italics">[see Use in Specific Populations (<a href="#s88">8.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-2.3.5"></a><p></p>
<p class="First"><span class="Underline">Nursing Mothers</span> — Because the safety of duloxetine in infants is not known, nursing while on Cymbalta is not recommended <span class="Italics">[see Use in Specific Populations (<a href="#s92">8.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Discontinuing Cymbalta</h2>
<p class="First">Symptoms associated with discontinuation of Cymbalta and other SSRIs and SNRIs have been reported. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible <span class="Italics">[see Warnings and Precautions (<a href="#s37">5.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Switching Patients to or from a Monoamine Oxidase Inhibitor</h2>
<p class="First">At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Cymbalta. In addition, at least 5 days should be allowed after stopping Cymbalta before starting an MAOI <span class="Italics">[see Contraindications (<a href="#s28">4.1</a>) and Warnings and Precautions (<a href="#s35">5.4</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s25"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Cymbalta is available as delayed release capsules:</p>
<dl>
<dt> </dt>
<dd>20mg opaque green capsules imprinted with “Lilly 3235 20mg?</dd>
<dt> </dt>
<dd>30mg opaque white and blue capsules imprinted with “Lilly 3240 30mg?</dd>
<dt> </dt>
<dd>60mg opaque green and blue capsules imprinted with “Lilly 3237 60mg?</dd>
<dt> </dt>
<dd>60mg opaque green and blue capsules imprinted with “Lilly 3270 60mg?</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s27"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Monoamine Oxidase Inhibitors</h2>
<p class="First">Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serious, sometimes fatal, drug interactions with serotonergic drugs. These interactions may include <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. These reactions have also been reported in patients who have recently discontinued serotonin reuptake inhibitors and are then started on an MAOI. Some cases presented with features resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> <span class="Italics">[see Dosage and Administration (<a href="#s24">2.5</a>) and Warnings and Precautions (<a href="#s35">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Uncontrolled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">In clinical trials, Cymbalta use was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; therefore, its use should be avoided in patients with uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> <span class="Italics">[see Warnings and Precautions (<a href="#s46">5.12</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s30"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">
									Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. </p>
<p>
									Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.</p>
<p>
									The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <a href="#t1">Table 1</a>.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1</span></caption>
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Age Range</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">Increases Compared to Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">&lt;18</td>
<td class="Botrule Rrule" align="center" valign="middle">14 additional cases</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">18-24</td>
<td class="Botrule Rrule" align="center" valign="middle">5 additional cases</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">Decreases Compared to Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">25-64</td>
<td class="Botrule Rrule" align="center" valign="middle">1 fewer case</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">≥65</td>
<td class="Botrule Rrule" align="center" valign="middle">6 fewer cases</td>
</tr>
</tbody>
</table>
<p>
									No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>
									It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>
									The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>
									Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.</p>
<p>
									If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that discontinuation can be associated with certain symptoms <span class="Italics">[see Dosage and Administration (<a href="#s23">2.4</a>) and Warnings and Precautions (<a href="#s37">5.6</a>)</span> for descriptions of the risks of discontinuation of Cymbalta<span class="Italics">]</span>.</p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Cymbalta should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Bold">Screening Patients for Bipolar Disorder</span> — A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that Cymbalta (duloxetine) is not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hepatotoxicity</h2>
<p class="First">
									There have been reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, sometimes fatal, in patients treated with Cymbalta. These cases have presented as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, and elevation of transaminase levels to more than twenty times the upper limit of normal with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, reflecting a mixed or hepatocellular pattern of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. Cymbalta should be discontinued in patients who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established.</p>
<p>
									Cases of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> with minimal elevation of transaminase levels have also been reported. Other postmarketing reports indicate that elevated transaminases, bilirubin, and alkaline phosphatase have occurred in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> or cirrhosis.</p>
<p>
									Cymbalta increased the risk of elevation of serum transaminase levels in development program clinical trials. Liver transaminase elevations resulted in the discontinuation of 0.3% (82/27,229) of Cymbalta-treated patients. In these patients, the median time to detection of the transaminase elevation was about two months. In placebo-controlled trials in any indication, elevation of ALT &gt;3 times the upper limit of normal occurred in 1.1% (85/7,632) of Cymbalta-treated patients compared to 0.2% (13/5,578) of placebo-treated patients. In placebo-controlled studies using a fixed dose design, there was evidence of a dose response relationship for ALT and AST elevation of &gt;3 times the upper limit of normal and &gt;5 times the upper limit of normal, respectively.</p>
<p>
									Because it is possible that duloxetine and alcohol may interact to cause <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> or that duloxetine may aggravate pre-existing liver disease, Cymbalta should ordinarily not be prescribed to patients with substantial alcohol use or evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First">
									<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been reported with therapeutic doses of duloxetine. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> tend to occur within the first week of therapy but can occur at any time during duloxetine treatment, particularly after dose increases. The risk of blood pressure decreases may be greater in patients taking concomitant medications that induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (such as antihypertensives) or are potent CYP1A2 inhibitors <span class="Italics">[see Warnings and Precautions (<a href="#s41">5.10</a>) and Drug Interactions (<a href="#s69">7.1</a>)]</span> and in patients taking duloxetine at doses above 60 mg daily. Consideration should be given to discontinuing duloxetine in patients who experience symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> during duloxetine therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like Reactions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Cymbalta treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, in its most severe form can resemble <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, which includes <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuation of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or NMS-like signs and symptoms.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The concomitant use of Cymbalta with MAOIs intended to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is contraindicated <span class="Italics">[see Contraindications (<a href="#s28">4.1</a>)]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>If concomitant treatment of Cymbalta with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases <span class="Italics">[see Drug Interactions (<a href="#s83">7.15</a>)]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The concomitant use of Cymbalta with serotonin precursors (such as tryptophan) is not recommended <span class="Italics">[see Drug Interactions (<a href="#s82">7.14</a>)]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>
Treatment with duloxetine and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">
									SSRIs and SNRIs, including duloxetine, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to SSRIs and SNRIs use have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>.</p>
<p>
									Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Discontinuation of Treatment with Cymbalta</h2>
<p class="First">
									Discontinuation symptoms have been systematically evaluated in patients taking duloxetine. Following abrupt or tapered discontinuation in placebo-controlled clinical trials, the following symptoms occurred at a rate greater than or equal to 1% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p>
									During marketing of other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Although these events are generally self-limiting, some have been reported to be severe.</p>
<p>
									Patients should be monitored for these symptoms when discontinuing treatment with Cymbalta. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate <span class="Italics">[see Dosage and Administration (<a href="#s23">2.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<p class="First">In placebo-controlled trials in patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> was reported in 0.1% (2/2,489) of duloxetine-treated patients and 0.1% (1/1,625) of placebo-treated patients. No activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> was reported in DPNP, GAD, or <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> placebo-controlled trials. Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> or <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has been reported in a small proportion of patients with mood disorders who were treated with other marketed drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. As with these other agents, Cymbalta should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">Duloxetine has not been systematically evaluated in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, and such patients were excluded from clinical studies. In placebo-controlled clinical trials, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occurred in 0.03% (3/9,445) of patients treated with duloxetine and 0.01% (1/6,770) of patients treated with placebo. Cymbalta should be prescribed with care in patients with a history of a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Effect on Blood Pressure</h2>
<p class="First">In clinical trials across indications, relative to placebo, duloxetine treatment was associated with mean increases of up to 2.1 mm Hg in systolic blood pressure and up to 2.3 mm Hg in diastolic blood pressure. There was no significant difference in the frequency of sustained (3 consecutive visits) elevated blood pressure. In a clinical pharmacology study designed to evaluate the effects of duloxetine on various parameters, including blood pressure at supratherapeutic doses with an accelerated dose titration, there was evidence of increases in supine blood pressure at doses up to 200 mg twice daily. At the highest 200 mg twice daily dose, the increase in mean pulse rate was 5.0 to 6.8 beats and increases in mean blood pressure were 4.7 to 6.8 mm Hg (systolic) and 4.5 to 7 mm Hg (diastolic) up to 12 hours after dosing.</p>
<p>Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment <span class="Italics">[see Adverse Reactions (<a href="#e68">6.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Clinically Important Drug Interactions</h2>
<p class="First">Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-5.10.1"></a><p></p>
<p class="First"><span class="Underline">Potential for Other Drugs to Affect Cymbalta</span></p>
<p><span class="Italics">CYP1A2 Inhibitors</span> — Co-administration of Cymbalta with potent CYP1A2 inhibitors should be avoided <span class="Italics">[see Drug Interactions (<a href="#s69">7.1</a>)]</span>.</p>
<p><span class="Italics">CYP2D6 Inhibitors</span> — Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 would be expected to, and does, result in higher concentrations (on average of 60%) of duloxetine <span class="Italics">[see Drug Interactions (<a href="#s70">7.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-5.10.2"></a><p></p>
<p class="First"><span class="Underline">Potential for Cymbalta to Affect Other Drugs</span></p>
<p><span class="Italics">Drugs Metabolized by CYP2D6</span> — Co-administration of Cymbalta with drugs that are extensively metabolized by CYP2D6 and that have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Cymbalta. Because of the risk of serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> potentially associated with elevated plasma levels of thioridazine, Cymbalta and thioridazine should not be co-administered <span class="Italics">[see Drug Interactions (<a href="#s77">7.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-5.10.3"></a><p></p>
<p class="First"><span class="Underline">Other Clinically Important Drug Interactions</span></p>
<p><span class="Italics">Alcohol</span> — Use of Cymbalta concomitantly with heavy alcohol intake may be associated with severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. For this reason, Cymbalta should ordinarily not be prescribed for patients with substantial alcohol use <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.2</a>) and Drug Interactions (<a href="#s84">7.16</a>)]</span>.</p>
<p><span class="Italics">CNS Acting Drugs</span> — Given the primary CNS effects of Cymbalta, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action <span class="Italics">[see Warnings and Precautions (<a href="#s41">5.10</a>) and Drug Interactions (<a href="#s85">7.17</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First">
																		<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SSRIs and SNRIs, including Cymbalta. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported and appeared to be reversible when Cymbalta was discontinued. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk <span class="Italics">[see Use in Specific Populations (<a href="#s94">8.5</a>)]</span>. Discontinuation of Cymbalta should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted.</p>
<p>
																		Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. More severe and/or acute cases have been associated with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Use in Patients with Concomitant Illness</h2>
<p class="First">Clinical experience with Cymbalta in patients with concomitant systemic illnesses is limited. There is no information on the effect that alterations in gastric motility may have on the stability of Cymbalta's enteric coating. In extremely acidic conditions, Cymbalta, unprotected by the enteric coating, may undergo hydrolysis to form naphthol. Caution is advised in using Cymbalta in patients with conditions that may slow gastric emptying (e.g., some diabetics).</p>
<p>Cymbalta has not been systematically evaluated in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-5.12.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span> — Cymbalta should ordinarily not be used in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics"> [see Dosage and Administration (<a href="#s17">2.3</a>), Warnings and Precautions (<a href="#s33">5.2</a>), and Use in Specific Populations (<a href="#s98">8.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-5.12.2"></a><p></p>
<p class="First"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span> — Cymbalta should ordinarily not be used in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min). Increased plasma concentration of duloxetine, and especially of its metabolites, occur in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (requiring dialysis) <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>) and Use in Specific Populations (<a href="#s99">8.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-5.12.3"></a><p></p>
<p class="First"><span class="Underline">Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span> — In clinical trials, Cymbalta was associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; therefore, it should be used cautiously in patients with controlled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> <span class="Italics">[see Contraindications (<a href="#s29">4.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-5.12.4"></a><p></p>
<p class="First"><span class="Underline">Glycemic Control in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span> — As observed in DPNP trials, Cymbalta treatment worsens glycemic control in some patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. In three clinical trials of Cymbalta for the management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span>, the mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was approximately 12 years, the mean baseline fasting blood glucose was 176 mg/dL, and the mean baseline hemoglobin A<span class="Sub">1c</span> (HbA<span class="Sub">1c</span>) was 7.8%. In the 12-week acute treatment phase of these studies, Cymbalta was associated with a small increase in mean fasting blood glucose as compared to placebo. In the extension phase of these studies, which lasted up to 52 weeks, mean fasting blood glucose increased by 12 mg/dL in the Cymbalta group and decreased by 11.5 mg/dL in the routine care group. HbA<span class="Sub">1c</span> increased by 0.5% in the Cymbalta and by 0.2% in the routine care groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">Urinary Hesitation</span> and Retention</h2>
<p class="First">
									Cymbalta is in a class of drugs known to affect urethral resistance. If symptoms of <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span> develop during treatment with Cymbalta, consideration should be given to the possibility that they might be drug-related.</p>
<p>
									In post marketing experience, cases of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have been observed. In some instances of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> associated with duloxetine use, hospitalization and/or catheterization has been needed.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s52"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Laboratory Tests</h2>
<p class="First">No specific laboratory tests are recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s53"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Data Sources</h2>
<p class="First">The data described below reflect exposure to duloxetine in placebo-controlled trials for MDD (N=2,327), GAD (N=668), DPNP (N=568), and FM (N=876). The population studied was 17 to 89 years of age; 64.8%, 64.7%, 38.7%, and 94.6% female; and 85.5%, 84.6%, 77.6%, and 88% Caucasian for MDD, GAD, DPNP, and FM, respectively. Most patients received doses of a total of 60 to 120 mg per day <span class="Italics">[see Clinical Studies (<a href="#s118">14</a>)]</span>.</p>
<p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Reactions reported during the studies were not necessarily caused by the therapy, and the frequencies do not reflect investigator impression (assessment) of causality.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Adverse Reactions Reported as Reasons for Discontinuation of Treatment in Placebo-Controlled Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e56"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Underline">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></span> — Approximately 9% (209/2,327) of the patients who received duloxetine in placebo-controlled trials for MDD discontinued treatment due to an adverse reaction, compared with 4.7% (68/1,460) of the patients receiving placebo. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> (duloxetine 1.3%, placebo 0.5%) was the only common adverse reaction reported as a reason for discontinuation and considered to be drug-related (i.e., discontinuation occurring in at least 1% of the duloxetine-treated patients and at a rate of at least twice that of placebo).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e57"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></span> — Approximately 15.3% (102/668) of the patients who received duloxetine in placebo-controlled trials for GAD discontinued treatment due to an adverse reaction, compared with 4.0% (20/495) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (duloxetine 3.7%, placebo 0.2%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (duloxetine 1.3%, placebo 0.0%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (duloxetine 1.0%, placebo 0.2%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e58"></a><a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span> — Approximately 14.3% (81/568) of the patients who received duloxetine in placebo-controlled trials for DPNP discontinued treatment due to an adverse reaction, compared with 7.2% (16/223) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (duloxetine 3.5%, placebo 0.4%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (duloxetine 1.6%, placebo 0.4%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (duloxetine 1.6%, placebo 0.0%), and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (duloxetine 1.1%, placebo 0.0%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e59"></a><a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></span> — Approximately 19.5% (171/876) of the patients who received duloxetine in 3 to 6 month placebo-controlled trials for FM discontinued treatment due to an adverse reaction, compared with 11.8% (63/535) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (duloxetine 1.9%, placebo 0.7%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (duloxetine 1.5%, placebo 0.0%), and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (duloxetine 1.3%, placebo 0.2%).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Adverse Reactions Occurring at an Incidence of 5% or More and at least Twice Placebo Among Duloxetine-Treated Patients in Placebo-Controlled Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e61"></a><a name="section-6.3.1"></a><p></p>
<p class="First"><span class="Underline">Pooled Trials for all Approved Indications</span> — The most commonly observed adverse reactions in Cymbalta-treated patients (incidence of at least 5% and at least twice the incidence in placebo patients) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>.</p>
<p>In addition to the adverse reactions listed above, DPNP trials also included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Adverse Reactions Occurring at an Incidence of 5% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</h2>
<p class="First"><a href="#t2">Table 2</a> gives the incidence of treatment-emergent adverse reactions in placebo-controlled trials for approved indications that occurred in 5% or more of patients treated with duloxetine and with an incidence greater than placebo.</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Treatment-Emergent Adverse Reactions: Incidence of 5% or More in Placebo-Controlled Trials of Approved Indications</span></caption>
<col align="left" width="29.800%">
<col align="left" width="34.033%">
<col align="left" width="36.167%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> Events for which there was a significant dose-dependent relationship in fixed-dose studies, excluding three MDD studies which did not have a placebo lead-in period or dose titration.</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span> Also includes <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">c</span> Also includes <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span>, <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakening</span>, and <span class="product-label-link" type="condition" conceptid="4243368" conceptname="Initial insomnia">initial insomnia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">d</span> Also includes <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span> and sedation</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">e</span> Also includes <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span><br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Cymbalta<br>(N=4843)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Placebo<br>(N=3048)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">25</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">9</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">16</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">15</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">14</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">6</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">11</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">6</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><span class="Sup">a,c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">11</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">7</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">11</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">6</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">a,d</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">11</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">3</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">11</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">4</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">10</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">7</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span><span class="Sup">a,e</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">8</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">2</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">7</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">2</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e63"></a><a name="section-6.5"></a><p></p>
<h2>6.5 Adverse Reactions Occurring at an Incidence of 2% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e64"></a><a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Underline">Pooled MDD and GAD Trials</span> — <a href="#t3">Table 3</a> gives the incidence of treatment-emergent adverse reactions in MDD and GAD placebo-controlled trials for approved indications that occurred in 2% or more of patients treated with duloxetine and with an incidence greater than placebo.</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Treatment-Emergent Adverse Reactions: Incidence of 2% or More in MDD and GAD Placebo-Controlled Trials</span></caption>
<col align="left" width="45.533%">
<col align="left" width="26.800%">
<col align="left" width="27.667%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> Events for which there was a significant dose-dependent relationship in fixed-dose studies, excluding three MDD studies which did not have a placebo lead-in period or dose titration.</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span> Also includes <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, and <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">c</span> Also includes <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">d</span> Also includes <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">e</span> Also includes <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span> and sedation</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">f</span> Also includes <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span>, <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakening</span>, and <span class="product-label-link" type="condition" conceptid="4243368" conceptname="Initial insomnia">initial insomnia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">g</span> Also includes <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">h</span> Also includes <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">i</span> Also includes <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">j</span> Also includes <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">k</span> Male patients only</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">l</span> Also includes <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">ejaculation failure</span> and ejaculation dysfunction<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">System Organ Class / Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Cymbalta<br>(N=2995)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo<br>(N=1955)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">25</td>
<td class="Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><span class="Sup">a</span>
</td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span><span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">e</span>
</td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><span class="Sup">f</span>
</td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span><span class="Sup">g</span>
</td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span><span class="Sup">h</span>
</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4090570" conceptname="Painful orgasm">Orgasm abnormal</span><span class="Sup">i</span>
</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span><span class="Sup">j</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span><span class="Sup">k</span>
</td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4036117" conceptname="Late ejaculation">Ejaculation delayed</span><span class="Sup">a,k</span>
</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation disorder</span><span class="Sup">k,l</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawning</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e65"></a><a name="section-6.5.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span> — <a href="#t4">Table 4</a> gives the incidence of treatment-emergent adverse events that occurred in 2% or more of patients treated with Cymbalta in the premarketing acute phase of DPNP placebo-controlled trials (doses of 20 to 120 mg/day) and with an incidence greater than placebo.</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Treatment-Emergent Adverse Reactions Incidence of 2% or More in DPNP Placebo-Controlled Trials</span></caption>
<col align="left" width="41.317%">
<col align="left" width="15.006%">
<col align="left" width="15.006%">
<col align="left" width="15.006%">
<col align="left" width="13.665%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Male patients only.</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom"><span class="Bold">System Organ Class /<br>  Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Cymbalta <br>20 mg once daily <br>(N=115)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Cymbalta <br>60 mg once daily <br>(N=228)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Cymbalta <br>60 mg twice daily <br>(N=225)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo <br><br> (N=223)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">14</td>
<td class="Rrule" align="center" valign="top">22</td>
<td class="Rrule" align="center" valign="top">30</td>
<td class="Rrule" align="center" valign="top">9</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">13</td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top">12</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Lrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration<br>  Site Conditions</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">12</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">8</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Musculoskeletal and Connective Tissue<br>  Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramp</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">21</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center" valign="top">13</td>
<td class="Rrule" align="center" valign="top">13</td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Rrule" align="center" valign="top">14</td>
<td class="Rrule" align="center" valign="top">17</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Renal and Urinary Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Pollakiuria</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Reproductive System and Breast   Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory, Thoracic and Mediastinal<br>  Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous<br>  Tissue Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e66"></a><a name="section-6.5.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></span> — <a href="#t5">Table 5</a> gives the incidence of treatment-emergent adverse events that occurred in 2% or more of patients treated with Cymbalta in the premarketing acute phase of FM placebo-controlled trials and with an incidence greater than placebo.</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Treatment-Emergent Adverse Reactions: Incidence of 2% or More in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Placebo-Controlled Trials</span></caption>
<col align="left" width="48.933%">
<col align="left" width="25.533%">
<col align="left" width="25.533%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> Male patients only (N = 46 duloxetine-treated patients versus 26 placebo patients)</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span> Also includes <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">c</span> Also includes <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">d</span> Also includes <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span> and sedation</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">e</span> Also includes <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span>, <span class="product-label-link" type="condition" conceptid="4283230" conceptname="Terminal insomnia">early morning awakening</span>, and <span class="product-label-link" type="condition" conceptid="4243368" conceptname="Initial insomnia">initial insomnia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">f</span> Also includes <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">g</span> Also includes <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">h</span> Also includes <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span></p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">i</span> Also includes <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span></p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">j</span> Also includes <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">ejaculation failure</span> and ejaculation dysfunction</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<br><span class="Bold">System Organ Class / Adverse Reaction</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Cymbalta<br>(N=876)</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=535)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center" valign="top">29</td>
<td class="Rrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center" valign="top">18</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center" valign="top">12</td>
<td class="Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="top">15</td>
<td class="Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="40478941" conceptname="Seasonal allergy">Seasonal allergy</span></td>
<td class="Lrule Rrule" align="center" valign="top">3</td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Lrule Rrule" align="center" valign="top">7</td>
<td class="Lrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Lrule Rrule" align="center" valign="top">3</td>
<td class="Lrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="201218" conceptname="Epidemic vomiting syndrome">Gastroenteritis viral</span></td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left" valign="top"><span class="Bold">Investigations</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
<td class="Lrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span><span class="Sup">c</span>
</td>
<td class="Lrule Rrule" align="center" valign="top">11</td>
<td class="Lrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left" valign="top">
<span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Lrule Rrule" align="center" valign="top">5</td>
<td class="Lrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center" valign="top">20</td>
<td class="Rrule" align="center" valign="top">12</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><span class="Sup">d</span>
</td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paraesthesia</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><span class="Sup">e</span>
</td>
<td class="Rrule" align="center" valign="top">16</td>
<td class="Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span><span class="Sup">f</span>
</td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span><span class="Sup">g</span>
</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4090570" conceptname="Painful orgasm">Orgasm abnormal</span><span class="Sup">h</span>
</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span><span class="Sup">i</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></td>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Lrule Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation disorder</span><span class="Sup">a,j</span>
</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="196158" conceptname="Disorder of penis">Penis disorder</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Rrule" align="center" valign="top">7</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Pruritis</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flush</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e67"></a><a name="section-6.6"></a><p></p>
<h2>6.6 Effects on Male and Female Sexual Function</h2>
<p class="First">Changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of psychiatric disorders or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, but they may also be a consequence of pharmacologic treatment. Because adverse sexual reactions are presumed to be voluntarily underreported, the Arizona Sexual Experience Scale (ASEX), a validated measure designed to identify sexual side effects, was used prospectively in 4 MDD placebo-controlled trials. In these trials, as shown in <a href="#t6">Table 6</a> below, patients treated with Cymbalta experienced significantly more <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, as measured by the total score on the ASEX, than did patients treated with placebo. Gender analysis showed that this difference occurred only in males. Males treated with Cymbalta experienced more difficulty with ability to reach orgasm (ASEX Item 4) than males treated with placebo. Females did not experience more <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> on Cymbalta than on placebo as measured by ASEX total score. Negative numbers signify an improvement from a baseline level of dysfunction, which is commonly seen in depressed patients. Physicians should routinely inquire about possible sexual side effects.</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Mean Change in ASEX Scores by Gender in MDD Placebo-Controlled Trials</span></caption>
<col align="left" width="41.317%">
<col align="left" width="15.246%">
<col align="left" width="15.246%">
<col align="left" width="15.246%">
<col align="left" width="12.945%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> n=Number of patients with non-missing change score for ASEX total</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">b</span> p=0.013 versus placebo</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">c</span> p&lt;0.001 versus placebo</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Male Patients</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Female Patients</span><span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Cymbalta<br>(n=175)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo<br>(n=83)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Cymbalta<br>(n=241)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo<br>(n=126)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">ASEX Total (Items 1-5)</td>
<td class="Rrule" align="center" valign="top">0.56<span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="top">-1.07</td>
<td class="Rrule" align="center" valign="top">-1.15</td>
<td class="Rrule" align="center" valign="top">-1.07</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 1 — Sex drive</td>
<td class="Rrule" align="center" valign="top">-0.07</td>
<td class="Rrule" align="center" valign="top">-0.12</td>
<td class="Rrule" align="center" valign="top">-0.32</td>
<td class="Rrule" align="center" valign="top">-0.24</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 2 — Arousal</td>
<td class="Rrule" align="center" valign="top">0.01</td>
<td class="Rrule" align="center" valign="top">-0.26</td>
<td class="Rrule" align="center" valign="top">-0.21</td>
<td class="Rrule" align="center" valign="top">-0.18</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 3 — Ability to achieve   erection (men); Lubrication (women)</td>
<td class="Rrule" align="center" valign="top">0.03</td>
<td class="Rrule" align="center" valign="top">-0.25</td>
<td class="Rrule" align="center" valign="top">-0.17</td>
<td class="Rrule" align="center" valign="top">-0.18</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 4 — Ease of reaching orgasm</td>
<td class="Rrule" align="center" valign="top">0.40<span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="top">-0.24</td>
<td class="Rrule" align="center" valign="top">-0.09</td>
<td class="Rrule" align="center" valign="top">-0.13</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Item 5 — Orgasm satisfaction</td>
<td class="Botrule Rrule" align="center" valign="top">0.09</td>
<td class="Botrule Rrule" align="center" valign="top">-0.13</td>
<td class="Botrule Rrule" align="center" valign="top">-0.11</td>
<td class="Botrule Rrule" align="center" valign="top">-0.17</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e68"></a><a name="section-6.7"></a><p></p>
<h2>6.7 Vital Sign Changes</h2>
<p class="First">In clinical trials across indications, relative to placebo, duloxetine treatment was associated with mean increases of up to 2.1 mm Hg in systolic blood pressure and up to 2.3 mm Hg in diastolic blood pressure. There was no significant difference in the frequency of sustained (3 consecutive visits) elevated blood pressure <span class="Italics">[see Warnings and Precautions (<a href="#s34">5.3</a> and <a href="#s40">5.9</a>)]</span>.</p>
<p>Duloxetine treatment, for up to 26 weeks in placebo-controlled trials typically caused a small increase in heart rate compared to placebo of up to 3-4 beats per minute.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e69"></a><a name="section-6.8"></a><p></p>
<h2>6.8 Weight Changes</h2>
<p class="First">In placebo-controlled clinical trials, MDD and GAD patients treated with Cymbalta for up to 10 weeks experienced a mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of approximately 0.5 kg, compared with a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of approximately 0.2 kg in placebo-treated patients. In DPN placebo-controlled clinical trials, patients treated with Cymbalta for up to 13-weeks experienced a mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of approximately 1.1 kg, compared with a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of approximately 0.2 kg in placebo-treated patients. In <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> studies, patients treated with Cymbalta for up to 26 weeks experienced a mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of approximately 0.4 kg compared with a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of approximately 0.3 kg in placebo-treated patients. In one long-term <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> 60-week uncontrolled study, duloxetine patients had a mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span> of 0.7 kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e70"></a><a name="section-6.9"></a><p></p>
<h2>6.9 Laboratory Changes</h2>
<p class="First">Cymbalta treatment in placebo-controlled clinical trials, was associated with small mean increases from baseline to endpoint in ALT, AST, CPK, and alkaline phosphatase; infrequent, modest, transient, abnormal values were observed for these analytes in Cymbalta-treated patients when compared with placebo-treated patients <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e71"></a><a name="section-6.10"></a><p></p>
<h2>6.10 Electrocardiogram Changes</h2>
<p class="First">Electrocardiograms were obtained from duloxetine-treated patients and placebo-treated patients in clinical trials lasting up to 13 weeks. No clinically significant differences were observed for QTc, QT, PR, and QRS intervals between duloxetine-treated and placebo-treated patients. There were no differences in clinically meaningful QTcF elevations between duloxetine and placebo. In a positive-controlled study in healthy volunteers using duloxetine up to 200 mg twice daily, no prolongation of the corrected QT interval was observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e72"></a><a name="section-6.11"></a><p></p>
<h2>6.11 Other Adverse Reactions Observed During the Premarketing and Postmarketing Clinical Trial Evaluation of Duloxetine</h2>
<p class="First">Following is a list of treatment-emergent adverse reactions reported by patients treated with duloxetine in clinical trials. In clinical trials of all indications, 27,229 patients were treated with duloxetine. Of these, 29% (7,886) took duloxetine for at least 6 months, and 13.3% (3,614) for at least one year. The following listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo.</p>
<p>Reactions are categorized by body system according to the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Bold">Ear and Labyrinth Disorders</span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span> and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span> — <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, and <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>.</p>
<p><span class="Bold">General Disorders and Administration Site Conditions</span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling hot</span> and/or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span> — <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>.</p>
<p><span class="Bold">Investigations</span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>; <span class="Italics">Infrequent:</span> blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased.</p>
<p><span class="Bold">Metabolism and Nutrition Disorders</span> — <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>.</p>
<p><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">muscle tightness</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and parasthesia/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, and <span class="product-label-link" type="condition" conceptid="4100068" conceptname="Wakefulness">poor quality sleep</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>.</p>
<p><span class="Bold">Psychiatric Disorders</span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span> and <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="4099943" conceptname="Bruxism">bruxism</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>/<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, and <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span>.</p>
<p><span class="Bold">Renal and Urinary Disorders</span> — <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">micturition urgency</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, and urine odor abnormal.</p>
<p><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>/<span class="product-label-link" type="condition" conceptid="4090570" conceptname="Painful orgasm">orgasm abnormal</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>, and <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>.</p>
<p><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>.</p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders</span> —<span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">dermatitis contact</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4059014" conceptname="Spontaneous bruising">increased tendency to bruise</span>, <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span> — <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">peripheral coldness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e73"></a><a name="section-6.12"></a><p></p>
<h2>6.12 Postmarketing Spontaneous Reports</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Cymbalta. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Adverse reactions reported since market introduction that were temporally related to duloxetine therapy and not mentioned elsewhere in labeling include: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> and <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span> (particularly early in treatment or after treatment discontinuation), <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, gynecological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs syndrome</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> upon treatment discontinuation, supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> (upon treatment discontinuation), <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> that have required drug discontinuation and/or hospitalization have been reported with duloxetine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s68"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Inhibitors of CYP1A2</h2>
<p class="First">When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C<span class="Sub">max</span> was increased about 2.5-fold, and duloxetine t<span class="Sub">1/2</span> was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin <span class="Italics">[see Warnings and Precautions (<a href="#s41">5.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Inhibitors of CYP2D6</h2>
<p class="First">Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) <span class="Italics">[see Warnings and Precautions (<a href="#s41">5.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Dual Inhibition of CYP1A2 and CYP2D6</h2>
<p class="First">Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C<span class="Sub">max</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</h2>
<p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SSRIs or SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued <span class="Italics">[see Warnings and Precautions (<a href="#s36">5.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Lorazepam</h2>
<p class="First">Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Temazepam</h2>
<p class="First">Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Drugs that Affect Gastric Acidity</h2>
<p class="First">Cymbalta has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. In extremely acidic conditions, Cymbalta, unprotected by the enteric coating, may undergo hydrolysis to form naphthol. Caution is advised in using Cymbalta in patients with conditions that may slow gastric emptying (e.g., some diabetics). Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine. However, co-administration of Cymbalta with aluminum- and magnesium-containing antacids (51 mEq) or Cymbalta with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose. It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption <span class="Italics">[see Warnings and Precautions (<a href="#s46">5.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Drugs Metabolized by CYP1A2</h2>
<p class="First"><span class="Italics">In vitro</span> drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in <span class="Italics">in vitro</span> studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1%-15%) and 20% (13%-27%) when co-administered with duloxetine (60 mg twice daily).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Drugs Metabolized by CYP2D6</h2>
<p class="First">Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold <span class="Italics">[see Warnings and Precautions (<a href="#s41">5.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-7.10"></a><p></p>
<h2>7.10 Drugs Metabolized by CYP2C9</h2>
<p class="First">Duloxetine does not inhibit the <span class="Italics">in vitro</span> enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-7.11"></a><p></p>
<h2>7.11 Drugs Metabolized by CYP3A</h2>
<p class="First">Results of <span class="Italics">in vitro</span> studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-7.12"></a><p></p>
<h2>7.12 Drugs Metabolized by CYP2C19</h2>
<p class="First">Results of <span class="Italics">in vitro</span> studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-7.13"></a><p></p>
<h2>7.13 Monoamine Oxidase Inhibitors</h2>
<p class="First"><span class="Italics">[see Dosage and Administration (<a href="#s24">2.5</a>), Contraindications (<a href="#s28">4.1</a>), and Warnings and Precautions (<a href="#s35">5.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-7.14"></a><p></p>
<h2>7.14 Serotonergic Drugs</h2>
<p class="First">Based on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort. The concomitant use of Cymbalta with other SSRIs, SNRIs or tryptophan is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-7.15"></a><p></p>
<h2>7.15 Triptans</h2>
<p class="First">There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of an SSRI and a triptan. If concomitant treatment of Cymbalta with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s84"></a><a name="section-7.16"></a><p></p>
<h2>7.16 Alcohol</h2>
<p class="First">When Cymbalta and ethanol were administered several hours apart so that peak concentrations of each would coincide, Cymbalta did not increase the impairment of mental and motor skills caused by alcohol.</p>
<p>In the Cymbalta clinical trials database, three Cymbalta-treated patients had <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> as manifested by ALT and total bilirubin elevations, with evidence of obstruction. Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.2</a> and <a href="#s41">5.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-7.17"></a><p></p>
<h2>7.17 CNS Drugs</h2>
<p class="First"><span class="Italics">[see Warnings and Precautions (<a href="#s41">5.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-7.18"></a><p></p>
<h2>7.18 Drugs Highly Bound to Plasma Protein</h2>
<p class="First">Because duloxetine is highly bound to plasma protein, administration of Cymbalta to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s87"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s88"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s89"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Teratogenic Effects, Pregnancy Category C</span> — In animal reproduction studies, duloxetine has been shown to have adverse effects on embryo/fetal and postnatal development.</p>
<p>When duloxetine was administered orally to pregnant rats and rabbits during the period of organogenesis, there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at doses up to 45 mg/kg/day (7 times the maximum recommended human dose [MRHD, 60 mg/day] and 4 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis, in rat; 15 times the MRHD and 7 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis in rabbit). However, fetal weights were decreased at this dose, with a no-effect dose of 10 mg/kg/day (2 times the MRHD and ≈1 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis in rat; 3 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis in rabbits).</p>
<p>When duloxetine was administered orally to pregnant rats throughout gestation and lactation, the survival of pups to 1 day postpartum and pup body weights at birth and during the lactation period were decreased at a dose of 30 mg/kg/day (5 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis); the no-effect dose was 10 mg/kg/day. Furthermore, behaviors consistent with increased reactivity, such as increased startle response to noise and decreased <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span> of locomotor activity, were observed in pups following maternal exposure to 30 mg/kg/day. Post-weaning growth and reproductive performance of the progeny were not affected adversely by maternal duloxetine treatment.</p>
<p>There are no adequate and well-controlled studies in pregnant women; therefore, duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s90"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Nonteratogenic Effects</span> — Neonates exposed to SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.4</a>)]</span>.</p>
<p>When treating pregnant women with Cymbalta during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering Cymbalta in the third trimester <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s91"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s92"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Duloxetine is excreted into the milk of lactating women. The estimated daily infant dose on a mg/kg basis is approximately 0.14% of the maternal dose. Because the safety of duloxetine in infants is not known, nursing while on Cymbalta is not recommended. However, if the physician determines that the benefit of duloxetine therapy for the mother outweighs any potential risk to the infant, no dosage adjustment is required as lactation did not influence duloxetine pharmacokinetics.</p>
<p>The disposition of duloxetine was studied in 6 lactating women who were at least 12 weeks postpartum. Duloxetine 40 mg twice daily was given for 3.5 days. Like many other drugs, duloxetine is detected in breast milk, and steady state concentrations in breast milk are about one-fourth those in plasma. The amount of duloxetine in breast milk is approximately 7 μg/day while on 40 mg BID dosing. The excretion of duloxetine metabolites into breast milk was not examined. Because the safety of duloxetine in infants is not known, nursing while on Cymbalta is not recommended <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s93"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in the pediatric population have not been established <span class="Italics">[see <a href="#s2">Boxed Warning</a> and Warnings and Precautions (<a href="#s31">5.1</a>)]</span>. Anyone considering the use of Cymbalta in a child or adolescent must balance the potential risks with the clinical need.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s94"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 2,418 patients in premarketing clinical studies of Cymbalta for MDD, 5.9% (143) were 65 years of age or over. Of the 1,074 patients in the DPNP premarketing studies, 33% (357) were 65 years of age or over. Of the 1,761 patients in FM premarketing studies, 7.9% (140) were 65 years of age or over. Premarketing clinical studies of GAD did not include sufficient numbers of subjects age 65 or over to determine whether they respond differently from younger subjects. In the MDD, DPNP, and FM studies, no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including Cymbalta have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event <span class="Italics">[see Warnings and Precautions (<a href="#s45">5.11</a>)]</span>.</p>
<p>The pharmacokinetics of duloxetine after a single dose of 40 mg were compared in healthy elderly females (65 to 77 years) and healthy middle-age females (32 to 50 years). There was no difference in the C<span class="Sub">max</span>, but the AUC of duloxetine was somewhat (about 25%) higher and the half-life about 4 hours longer in the elderly females. Population pharmacokinetic analyses suggest that the typical values for clearance decrease by approximately 1% for each year of age between 25 to 75 years of age; but age as a predictive factor only accounts for a small percentage of between-patient variability. Dosage adjustment based on the age of the patient is not necessary <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s95"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Gender</h2>
<p class="First">Duloxetine's half-life is similar in men and women. Dosage adjustment based on gender is not necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Smoking Status</h2>
<p class="First">Duloxetine bioavailability (AUC) appears to be reduced by about one-third in smokers. Dosage modifications are not recommended for smokers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s97"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Race</h2>
<p class="First">No specific pharmacokinetic study was conducted to investigate the effects of race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s98"></a><a name="section-8.9"></a><p></p>
<h2>8.9 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Patients with clinically evident <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> have decreased duloxetine metabolism and elimination. After a single 20 mg dose of Cymbalta, 6 cirrhotic patients with moderate liver impairment (Child-Pugh Class B) had a mean plasma duloxetine clearance about 15% that of age- and gender-matched healthy subjects, with a 5-fold increase in mean exposure (AUC). Although C<span class="Sub">max</span> was similar to normals in the cirrhotic patients, the half-life was about 3 times longer <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>) and Warnings and Precautions (<a href="#s46">5.12</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s99"></a><a name="section-8.10"></a><p></p>
<h2>8.10 Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Limited data are available on the effects of duloxetine in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD). After a single 60 mg dose of duloxetine, C<span class="Sub">max</span> and AUC values were approximately 100% greater in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> receiving chronic intermittent hemodialysis than in subjects with normal renal function. The elimination half-life, however, was similar in both groups. The AUCs of the major circulating metabolites, 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate, largely excreted in urine, were approximately 7- to 9-fold higher and would be expected to increase further with multiple dosing. Population PK analyses suggest that mild to moderate degrees of renal dysfunction (estimated CrCl 30-80 mL/min) have no significant effect on duloxetine apparent clearance <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>) and Warnings and Precautions (<a href="#s46">5.12</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s100"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s101"></a><a name="section-9.1"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">In animal studies, duloxetine did not demonstrate barbiturate-like (depressant) abuse potential.</p>
<p>While Cymbalta has not been systematically studied in humans for its potential for abuse, there was no indication of drug-seeking behavior in the clinical trials. However, it is not possible to predict on the basis of premarketing experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of Cymbalta (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s102"></a><a name="section-9.2"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">In <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> studies, duloxetine did not demonstrate <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>-producing potential in rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s103"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s104"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Signs and Symptoms</h2>
<p class="First">In postmarketing experience, fatal outcomes have been reported for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span>, primarily with mixed <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, but also with duloxetine only, at doses as low as 1000 mg. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (duloxetine alone or with mixed drugs) included <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s105"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">There is no specific antidote to Cymbalta, but if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, treatment should consist of those general measures employed in the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with any drug.</p>
<p>An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients.</p>
<p>Activated charcoal may be useful in limiting absorption of duloxetine from the gastrointestinal tract. Administration of activated charcoal has been shown to decrease AUC and C<span class="Sub">max</span> by an average of one-third, although some subjects had a limited effect of activated charcoal. Due to the large volume of distribution of this drug, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial.</p>
<p>In managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the possibility of multiple drug involvement should be considered. A specific caution involves patients who are taking or have recently taken Cymbalta and might ingest excessive quantities of a TCA. In such a case, decreased clearance of the parent tricyclic and/or its active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close medical observation <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.4</a>) and Drug Interactions (<a href="#s68">7</a>)]</span>. The physician should consider contacting a poison control center for additional information on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the <span class="Italics">Physicians' Desk Reference</span> (PDR).</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s106"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Cymbalta<span class="Sup">®</span> (duloxetine hydrochloride) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-(<span class="Italics">S</span>)-<span class="Italics">N</span>-methyl-γ-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The empirical formula is C<span class="Sub">18</span>H<span class="Sub">19</span>NOS•HCl, which corresponds to a molecular weight of 333.88. The structural formula is:</p>
<div class="Figure">
<a name="f01"></a><img alt="
Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67927928-c20f-4e12-a327-d26561d7810a&amp;name=cymbalta-01.jpg">
</div>
<p>Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water.</p>
<p>Each capsule contains enteric-coated pellets of 22.4, 33.7, or 67.3 mg of duloxetine hydrochloride equivalent to 20, 30, or 60 mg of duloxetine, respectively. These enteric-coated pellets are designed to prevent degradation of the drug in the acidic environment of the stomach. Inactive ingredients include FD&amp;C Blue No. 2, gelatin, hypromellose, hydroxypropyl methylcellulose acetate succinate, sodium lauryl sulfate, sucrose, sugar spheres, talc, titanium dioxide, and triethyl citrate. The 20 and 60 mg capsules also contain iron oxide yellow.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s107"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s108"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Although the exact mechanisms of the antidepressant, central <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s109"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Preclinical studies have shown that duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors <span class="Italics">in vitro</span>. Duloxetine does not inhibit monoamine oxidase (MAO).</p>
<p>Cymbalta is in a class of drugs known to affect urethral resistance. If symptoms of <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitation</span> develop during treatment with Cymbalta, consideration should be given to the possibility that they might be drug-related.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s110"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s111"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption and Distribution</span> — Orally administered duloxetine hydrochloride is well absorbed. There is a median 2 hour lag until absorption begins (T<span class="Sub">lag</span>), with maximal plasma concentrations (C<span class="Sub">max</span>) of duloxetine occurring 6 hours post dose. Food does not affect the C<span class="Sub">max</span> of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (AUC) by about 10%. There is a 3 hour delay in absorption and a one-third increase in apparent clearance of duloxetine after an evening dose as compared to a morning dose.</p>
<p>The apparent volume of distribution averages about 1640 L. Duloxetine is highly bound (&gt;90%) to proteins in human plasma, binding primarily to albumin and α<span class="Sub">1</span>-acid glycoprotein. The interaction between duloxetine and other highly protein bound drugs has not been fully evaluated. Plasma protein binding of duloxetine is not affected by renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s112"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination</span> — Biotransformation and disposition of duloxetine in humans have been determined following oral administration of <span class="Sup">14</span>C-labeled duloxetine. Duloxetine comprises about 3% of the total radiolabeled material in the plasma, indicating that it undergoes extensive metabolism to numerous metabolites. The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP1A2 and CYP2D6 catalyze the oxidation of the naphthyl ring <span class="Italics">in vitro</span>. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Only trace (&lt;1% of the dose) amounts of unchanged duloxetine are present in the urine. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces. Duloxetine undergoes extensive metabolism, but the major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s113"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s114"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s115"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span> — Duloxetine was administered in the diet to mice and rats for 2 years.</p>
<p>In female mice receiving duloxetine at 140 mg/kg/day (11 times the maximum recommended human dose [MRHD, 60 mg/day] and 6 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis), there was an increased incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas. The no-effect dose was 50 mg/kg/day (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis). Tumor incidence was not increased in male mice receiving duloxetine at doses up to 100 mg/kg/day (8 times the MRHD and 4 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis).</p>
<p>In rats, dietary doses of duloxetine up to 27 mg/kg/day in females (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis) and up to 36 mg/kg/day in males (6 times the MRHD and 3 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis) did not increase the incidence of tumors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s116"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span> — Duloxetine was not mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation assay (Ames test) and was not clastogenic in an <span class="Italics">in vivo</span> chromosomal aberration test in mouse bone marrow cells. Additionally, duloxetine was not genotoxic in an <span class="Italics">in vitro</span> mammalian forward gene mutation assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells or in an <span class="Italics">in vitro</span> unscheduled DNA synthesis (UDS) assay in primary rat hepatocytes, and did not induce sister chromatid exchange in Chinese hamster bone marrow <span class="Italics">in vivo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s117"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span> — Duloxetine administered orally to either male or female rats prior to and throughout mating at doses up to 45 mg/kg/day (7 times the maximum recommended human dose of 60 mg/day and 4 times the human dose of 120 mg/day on a mg/m<span class="Sup">2</span> basis) did not alter mating or fertility.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s118"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s119"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First">The efficacy of Cymbalta as a treatment for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> was established in 4 randomized, double-blind, placebo-controlled, fixed-dose studies in adult outpatients (18 to 83 years) meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>. In 2 studies, patients were randomized to Cymbalta 60 mg once daily (N=123 and N=128, respectively) or placebo (N=122 and N=139, respectively) for 9 weeks; in the third study, patients were randomized to Cymbalta 20 or 40 mg twice daily (N=86 and N=91, respectively) or placebo (N=89) for 8 weeks; in the fourth study, patients were randomized to Cymbalta 40 or 60 mg twice daily (N=95 and N=93, respectively) or placebo (N=93) for 8 weeks. There is no evidence that doses greater than 60 mg/day confer additional benefits.</p>
<p>In all 4 studies, Cymbalta demonstrated superiority over placebo as measured by improvement in the 17-item Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (HAMD-17) total score.</p>
<p>In all of these clinical studies, analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.</p>
<p>In another study, 533 patients meeting DSM-IV criteria for MDD received Cymbalta 60 mg once daily during an initial 12-week open-label treatment phase. Two hundred and seventy-eight patients who responded to open label treatment (defined as meeting the following criteria at weeks 10 and 12: a HAMD-17 total score ≤9, Clinical Global Impressions of Severity (CGI-S) ≤2, and not meeting the DSM-IV criteria for MDD) were randomly assigned to continuation of Cymbalta at the same dose (N=136) or to placebo (N=142) for 6 months. Patients on Cymbalta experienced a statistically significantly longer time to relapse of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> than did patients on placebo. Relapse was defined as an increase in the CGI–S score of ≥2 points compared with that obtained at week 12, as well as meeting the DSM-IV criteria for MDD at 2 consecutive visits at least 2 weeks apart, where the 2-week temporal criterion had to be satisfied at only the second visit. The effectiveness of Cymbalta in hospitalized patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s120"></a><a name="section-14.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">Generalized Anxiety Disorder</span></h2>
<p class="First">The efficacy of Cymbalta in the treatment of generalized <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> disorder (GAD) was established in 1 fixed-dose randomized, double-blind, placebo-controlled trial and 2 flexible-dose randomized, double-blind, placebo-controlled trials in adult outpatients between 18 and 83 years of age meeting the DSM-IV criteria for GAD.</p>
<p>In 1 flexible-dose study and in the fixed-dose study, the starting dose was 60 mg once daily where down titration to 30 mg once daily was allowed for tolerability reasons before increasing it to 60 mg once daily. Fifteen percent of patients were down titrated. One flexible-dose study had a starting dose of 30 mg once daily for 1 week before increasing it to 60 mg once daily.</p>
<p>The 2 flexible-dose studies involved dose titration with Cymbalta doses ranging from 60 mg once daily to 120 mg once daily (N=168 and N=162) compared to placebo (N=159 and N=161) over a 10-week treatment period. The mean dose for completers at endpoint in the flexible-dose studies was 104.75 mg/day. The fixed-dose study evaluated Cymbalta doses of 60 mg once daily (N=168) and 120 mg once daily (N=170) compared to placebo (N=175) over a 9-week treatment period. While a 120 mg/day dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit.</p>
<p>In all 3 studies, Cymbalta demonstrated superiority over placebo as measured by greater improvement in the Hamilton <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> Scale (HAM-A) total score and by the Sheehan <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Scale (SDS) global functional impairment score. The SDS is a widely used and well-validated scale that measures the extent emotional symptoms disrupt patient functioning in 3 life domains: work/school, social life/leisure activities, and family life/home responsibilities.</p>
<p>In another study, 887 patients meeting DSM-IV-TR criteria for GAD received Cymbalta 60 mg to 120 mg once daily during an initial 26-week open-label treatment phase. Four hundred and twenty-nine patients who responded to open-label treatment (defined as meeting the following criteria at weeks 24 and 26: a decrease from baseline HAM-A total score by at least 50% to a score no higher than 11, and a Clinical Global Impressions of Improvement [CGI-Improvement] score of 1 or 2) were randomly assigned to continuation of Cymbalta at the same dose (N = 216) or to placebo (N = 213) and were observed for relapse. Of the patients randomized, 73% had been in a responder status for at least 10 weeks. Relapse was defined as an increase in CGI-Severity score at least 2 points to a score ≥4 and a MINI (Mini-International Neuropsychiatric Interview) diagnosis of GAD (excluding duration), or discontinuation due to lack of efficacy. Patients taking Cymbalta experienced a statistically significantly longer time to relapse of GAD than did patients taking placebo.</p>
<p>Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s121"></a><a name="section-14.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></h2>
<p class="First">The efficacy of Cymbalta for the management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with diabetic peripheral neuropathy was established in 2 randomized, 12-week, double-blind, placebo-controlled, fixed-dose studies in adult patients having <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathic pain</span> for at least 6 months. Study 1 and 2 enrolled a total of 791 patients of whom 592 (75%) completed the studies. Patients enrolled had Type I or II <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus with a diagnosis of painful distal symmetrical sensorimotor <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> for at least 6 months. The patients had a baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥4 on an 11-point scale ranging from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (worst possible <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>). Patients were permitted up to 4 g of acetaminophen per day as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, in addition to Cymbalta. Patients recorded their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> daily in a diary.</p>
<p>Both studies compared Cymbalta 60 mg once daily or 60 mg twice daily with placebo. Study 1 additionally compared Cymbalta 20 mg with placebo. A total of 457 patients (342 Cymbalta, 115 placebo) were enrolled in Study 1 and a total of 334 patients (226 Cymbalta, 108 placebo) were enrolled in Study 2. Treatment with Cymbalta 60 mg one or two times a day statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores from baseline and increased the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. For various degrees of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline to study endpoint, Figures 1 and 2 show the fraction of patients achieving that degree of improvement. The figures are cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as week 1, which persisted throughout the study.</p>
<div class="Figure">
<a name="f02"></a><img alt="
Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67927928-c20f-4e12-a327-d26561d7810a&amp;name=cymbalta-02.jpg"><p class="MultiMediaCaption">Figure 1: Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by 24-Hour Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity - Study 1</p>
</div>
<div class="Figure">
<a name="f03"></a><img alt="
Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67927928-c20f-4e12-a327-d26561d7810a&amp;name=cymbalta-03.jpg"><p class="MultiMediaCaption">Figure 2: Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by 24-Hour Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity - Study 2</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e130"></a><a name="section-14.4"></a><p></p>
<h2>14.4 <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></h2>
<p class="First">The efficacy of Cymbalta for the management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> was established in two randomized, double-blind, placebo-controlled, fixed-dose studies in adult patients meeting the American College of Rheumatology criteria for <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (a history of widespread <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> for 3 months, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> present at 11 or more of the 18 specific tender point sites). Study 1 was three months in duration and enrolled female patients only. Study 2 was six months in duration and enrolled male and female patients. Approximately 25% of participants had a comorbid diagnosis of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD). Study 1 and 2 enrolled a total of 874 patients of whom 541 (62%) completed the studies. The patients had a baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of 6.5 on an 11-point scale ranging from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (worse possible <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>).</p>
<p>Both studies compared Cymbalta 60 mg once daily or 120 mg daily (given in divided doses in Study 1 and as a single daily dose in Study 2) with placebo. Study 2 additionally compared Cymbalta 20 mg with placebo during the initial three months of a six-month study. A total of 354 patients (234 Cymbalta, 120 placebo) were enrolled in Study 1 and a total of 520 patients (376 Cymbalta, 144 placebo) were enrolled in Study 2 (5% male, 95% female). Treatment with Cymbalta 60 mg or 120 mg daily statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores from baseline and increase the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> reduction was observed in patients both with and without comorbid MDD. However, the degree of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> reduction may be greater in patients with comorbid MDD. For various degrees of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline to study endpoint, Figures 3 and 4 show the fraction of patients achieving that degree of improvement. The figures are cumulative so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as week 1, which persisted throughout the study. Improvement was also demonstrated on measures of function (<span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Impact Questionnaires) and patient global impression of change (PGI). Neither study demonstrated a benefit of 120 mg compared to 60 mg, and a higher dose was associated with more adverse reactions and premature discontinuations of treatment.</p>
<div class="Figure">
<a name="f11"></a><img alt="
Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67927928-c20f-4e12-a327-d26561d7810a&amp;name=cymbalta-13.jpg"><p class="MultiMediaCaption">Figure 3: Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by 24-Hour Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity - Study 1</p>
</div>
<div class="Figure">
<a name="f12"></a><img alt="
Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67927928-c20f-4e12-a327-d26561d7810a&amp;name=cymbalta-14.jpg"><p class="MultiMediaCaption">Figure 4: Percentage of Patients Achieving Various Levels of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief as Measured by 24-Hour Average <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Severity - Study 2</p>
</div>
<p>Additionally, the benefit of up-titration in non-responders to Cymbalta at 60 mg/day was evaluated in a separate study. Patients were initially treated with Cymbalta 60 mg once daily for eight weeks in open-label fashion. Subsequently, completers of this phase were randomized to double-blind treatment with Cymbalta at either 60 mg once daily or 120 mg once daily. Those patients who were considered non-responders, where response was defined as at least a 30% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline at the end of the 8-week treatment, were no more likely to meet response criteria at the end of 60 weeks of treatment if blindly titrated to Cymbalta 120 mg as compared to those who were blindly continued on Cymbalta 60 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s122"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="s123"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Cymbalta is available as delayed release capsules in the following strengths, colors, imprints, and presentations:</p>
<table width="100%">
<col align="left" width="24.145%">
<col align="left" width="19.124%">
<col align="left" width="20.524%">
<col align="left" width="18.104%">
<col align="left" width="18.104%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">
			a
			</span>
			 equivalent to duloxetine base
			</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">
			† Identi-Dose® (unit dose medication, Lilly)
			</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">
			Features
			</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">
			Strengths
			</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
			20 mg<span class="Sup">a</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
			30 mg<span class="Sup">a</span></span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">
			60 mg<span class="Sup">a</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Body color
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Opaque green
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Opaque white
			</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
			Opaque green
			</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Cap color
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Opaque green
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Opaque blue
			</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
			Opaque blue
			</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Cap imprint
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Lilly 3235
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Lilly 3240
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Lilly 3237
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			Lilly 3270
			</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Body imprint
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			20mg
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			30mg
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			60mg
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			60mg
			</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Capsule number
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			PU3235
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			PU3240
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			PU3237
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			PU3270
			</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">
			Presentations and NDC Codes
			</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Bottles of 15
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			NA
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			21695-145-15
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			21695-146-15
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			21695-146-15
			</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
			Bottles of 30
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			NA
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			21695-145-30
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			21695-146-30
			</td>
<td class="Botrule Rrule" align="center" valign="top">
			21695-146-30
			</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s124"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s125"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved <a href="#s137">Medication Guide</a></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s126"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information on Medication Guide</h2>
<p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Cymbalta and should counsel them in its appropriate use. A patient Medication Guide About Using Antidepressants in Children and Teenagers is available for Cymbalta. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Cymbalta.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s127"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication <span class="Italics">[see <a href="#s2">Boxed Warning</a>, and Warnings and Precautions (<a href="#s31">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s128"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Medication Administration</h2>
<p class="First">Cymbalta should be swallowed whole and should not be chewed or crushed, nor should the capsule be opened and its contents be sprinkled on food or mixed with liquids. All of these might affect the enteric coating.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s129"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Continuing the Therapy Prescribed</h2>
<p class="First">While patients may notice improvement with Cymbalta therapy in 1 to 4 weeks, they should be advised to continue therapy as directed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s130"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Patients should be cautioned about the concomitant use of duloxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#s36">5.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s131"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Concomitant Medications</h2>
<p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter medications, since there is a potential for interactions <span class="Italics">[see Dosage and Administration (<a href="#s24">2.5</a>), Contraindications (<a href="#s28">4.1</a>), Warnings and Precautions (<a href="#s35">5.4</a> and <a href="#s41">5.10</a>), and Drug Interactions (<a href="#s68">7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s132"></a><a name="section-16.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of Cymbalta and triptans, tramadol or other serotonergic agents <span class="Italics">[see Warnings and Precautions (<a href="#s35">5.4</a>) and Drug Interactions (<a href="#s82">7.14</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s133"></a><a name="section-16.8"></a><p></p>
<h2>17.8 Pregnancy and Breast Feeding</h2>
<p class="First">Patients should be advised to notify their physician if they</p>
<ul class="Disc">
<li>become pregnant during therapy</li>
<li>intend to become pregnant during therapy</li>
<li>are breast feeding <span class="Italics">[see Dosage and Administration (<a href="#s17">2.3</a>) and Use in Specific Populations (<a href="#s88">8.1</a>, <a href="#s91">8.2</a>, and <a href="#s92">8.3</a>)]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s134"></a><a name="section-16.9"></a><p></p>
<h2>17.9 Alcohol</h2>
<p class="First">Although Cymbalta does not increase the impairment of mental and motor skills caused by alcohol, use of Cymbalta concomitantly with heavy alcohol intake may be associated with severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. For this reason, Cymbalta should ordinarily not be prescribed for patients with substantial alcohol use <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.2</a>) and Drug Interactions (<a href="#s84">7.16</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s135"></a><a name="section-16.10"></a><p></p>
<h2>17.10 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the period of initial use and subsequent dose escalation, and in association with the use of concomitant drugs that might potentiate the orthostatic effect of duloxetine <span class="Italics">[see Warnings and Precautions (<a href="#s34">5.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s136"></a><a name="section-16.11"></a><p></p>
<h2>17.11 Interference with Psychomotor Performance</h2>
<p class="First">Any psychoactive drug may impair judgment, thinking, or motor skills. Although in controlled studies Cymbalta has not been shown to impair psychomotor performance, cognitive function, or memory, it may be associated with sedation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Therefore, patients should be cautioned about operating hazardous machinery including automobiles, until they are reasonably certain that Cymbalta therapy does not affect their ability to engage in such activities.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="x99"></a><a name="section-17"></a><p></p>
<p class="First">Literature revised:  January 13, 2010</p>
<p><span class="Bold">Eli Lilly and Company<br>Indianapolis, IN 46285, USA</span></p>
<p>Copyright © 2004, 2010, Eli Lilly and Company. All rights reserved.</p>
<p>
							PV 7211 AMP
                  </p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s137"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illnesses, and Suicidal Thoughts or Actions</span></p>
<p>Read the Medication Guide that comes with your or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <span class="Bold">Talk to your, or your family member's, healthcare provider about:</span></p>
<ul class="Disc">
<li>all risks and benefits of treatment with antidepressant medicines</li>
<li>all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness</li>
</ul>
<p><span class="Bold">What is the most important information I should know about antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions?</span></p>
<ol class="Arabic">
<li><span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions.</span> These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.</li>
<li>
<span class="Bold">How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</span><ul class="Disc">
<li>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</li>
<li>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</li>
<li>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</li>
</ul>
</li>
</ol>
<p><span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<ul class="Disc">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">What else do I need to know about antidepressant medicines?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider.</span> Stopping an antidepressant medicine suddenly can cause other symptoms.</li>
<li>
<span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses.</span> It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.</li>
<li>
<span class="Bold">Antidepressant medicines have other side effects.</span> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</li>
<li>
<span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.</li>
<li>
<span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children.</span> Talk to your child's healthcare provider for more information.</li>
</ul>
<p></p>These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<p><span class="Italics">This Medication Guide has been approved by the US Food and Drug Administration for all antidepressants.</span></p>
<p>Patient Information revised December 4, 2008</p>
<p>PV 7090 AMP</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-19"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cymbalta, duloxetine HCl Delayed Release Capsules, 30 mg</p>  <p>     Bottles of 15 tablets.       <br>       NDC 21695-145-15<br> Bottles of 30 tablets.<br>    NDC 21695-145-30<br></p>
<p>Cymbalta, duloxetine HCl Delayed Release Capsules, 60 mg</p>  <p>     Bottles of 15 tablets.       <br>       NDC 21695-146-15<br> Bottles of 30 tablets.<br>    NDC 21695-146-30<br></p>
<p>Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. </p>
<p>Manufactured by:</p>
<p><span class="Bold">Eli Lilly and Company</span></p>
<p>Indianapolis, IN 46285</p>
<p>Repackaged by:<br><span class="Bold">Rebel Distributors Corp.</span><br>Thousand Oaks, CA 91320<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><img alt="Package Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67927928-c20f-4e12-a327-d26561d7810a&amp;name=146.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYMBALTA 		
					</strong><br><span class="contentTableReg">duloxetine hydrochloride capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-145(NDC:0002-3235)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Duloxetine hydrochloride</strong> (Duloxetine) </td>
<td class="formItem">Duloxetine</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromellose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MM2/S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Triethyl citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (opaque blue) , white (opaque white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LILLY;3240;30;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-145-15</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:21695-145-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021427</td>
<td class="formItem">08/24/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYMBALTA 		
					</strong><br><span class="contentTableReg">duloxetine hydrochloride capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-146(NDC:00002-3270)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Duloxetine hydrochloride</strong> (Duloxetine) </td>
<td class="formItem">Duloxetine</td>
<td class="formItem">60 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromellose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MM2/S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Triethyl citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (opaque green) , blue (opaque blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LILLY;3237;60;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-146-15</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:21695-146-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021427</td>
<td class="formItem">08/24/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp.
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp.</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c38b799-9341-4962-914b-fec751123b29</div>
<div>Set id: 67927928-c20f-4e12-a327-d26561d7810a</div>
<div>Version: 1</div>
<div>Effective Time: 20100331</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp.</div></p>
</body></html>
